Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease (PD)

Teva Pharmaceuticals

Status: Completed

Conditions: Parkinson's Disease

Treatments: Drug: Rasagiline mesylate

Study type: Observational

Funder types: Industry

Identifiers

NCT01032486

TNC-RAS-PD/01

REST (Other Identifier)

Details and patient eligibility

About

The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.

Enrollment: 120 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• idiopathic Parkinson's disease.
• eligible to Azilect® treatment as per Canadian product monograph

Exclusion criteria

• exclusion (e.g. drug-drug interactions, contraindications, warnings and precautions) based on the Canadian product monograph.
• investigational drug within 30 days prior to study
• use of Azilect® or selegiline within 60 days prior to study
• significant medical condition

Trial design

120 participants in 1 patient group

Azilect

Description:

Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.

Treatment:

Drug: Rasagiline mesylate